McKesson Corporation vs Meta Platforms Inc — how do they compare? McKesson Corporation trades at $930 (market cap $106.14B), while Meta Platforms Inc trades at $724.2 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 17.3× McKesson Corporation's market cap, and McKesson Corporation pays the higher dividend (0.41%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Meta Platforms Inc for 127 Days on average.
| MCK | META | |
|---|---|---|
Market Cap | $106.14B | $1.84T |
Volume | 794,405 | 12,743,601 |
Sector | Health | Media |
52-Week High | $995.69 | $777.59 |
52-Week Low | $725.17 | $525.72 |
Typical Hold Time | 74 Days | 127 Days |
Enterprise Value | $112.67B | $1.86T |
Dividend Yield | 0.41% | 0.29% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Meta Platforms (META) trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $719 and resistance at $726. Fundamentally, revenue grew to $200.97B in 2025 with a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a legal ruling on a youth addiction lawsuit in Massachusetts.
The outlook for META remains positive with strong analyst support—80% recommend Buy and a consensus price target of $781.00—driven by AI innovation and revenue growth. However, risks include regulatory challenges and high capital expenditures. Investors should weigh robust profitability against legal and competitive pressures in the social media and AI sectors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →